12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LCP-Tacro tacrolimus: Phase III data

The double-blind, double-dummy, international Phase III Study 3002 in 543 de novo kidney transplant recipients showed that once-daily LCP-Tacro met the primary endpoint of non-inferiority to twice-daily Prograf tacrolimus on a composite of biopsy-proven acute rejection, graft failure, death or loss to follow-up at 12 months (18.3% vs. 19.6%). Veloxis said the pre-specified non-inferiority margin was 10%. Rates of biopsy-proven acute rejection were 13.1% for LCP-Tacro vs. 13.5% for Prograf; rates of...

Read the full 348 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >